An accomplished biotech and healthcare executive, Ms. Deptula-Hicks most recently served as Chief Financial Officer of F-star ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

Multiple Key Leadership Appointments, Including Warner Biddle as CEO, Bringing Clinical, Commercial and Strategic Expertise in Cell Therapy Continuing to Advance Broad KYSA Clinical Development ...

CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from ...

Alison Hood, General Counsel Ms. Hood is an experienced general counsel in the biotech and pharma sector. She was previously VP & Head of Legal, International at Aimmune Therapeutics, a position she ...

Q3 2024 Earnings Call Transcript November 7, 2024 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Multiple sclerosis, a neuroinflammatory disease that affects nearly 3 million people worldwide, causes a loss of myelin, the ...

Q3 2024 Earnings Call Transcript November 4, 2024 TG Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Seaport Therapeutics (“Seaport or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the ...

Multiple sclerosis (MS) is a debilitating disease of the brain and spinal cord that impacts millions worldwide.